Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis

Toxicology in Vitro

Volumn 35, Issue , 2016, Pages 77-85

  Westra, Inge M ^a   Mutsaers, Henricus A M ^a   Luangmonkong, Theerut ^a   Hadi, Mackenzie ^a   Oosterhuis, Dorenda ^a   de Jong, Koert P ^b   Groothuis, Geny M M ^a   Olinga, Peter ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antifibrotic; Human precision cut liver slices; Liver fibrosis; TGF

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; HEAT SHOCK PROTEIN 47; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; PERINDOPRIL; PIRFENIDONE; PROCOLLAGEN; PROCOLLAGEN 1A1; PROTEIN INHIBITOR; RAC1 PROTEIN; ROSMARINIC ACID; SIS 3; SMAD3 PROTEIN; SORAFENIB; SUNITINIB; TETRANDRINE; UNCLASSIFIED DRUG; VALPROIC ACID; COLLAGEN TYPE I, ALPHA 1 CHAIN; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; SERPINH1 PROTEIN, HUMAN;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; BIOLOGICAL MODEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FEMALE; GENE CONTROL; GENE EXPRESSION; HSP47 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER FIBROSIS; LIVER SLICE; MALE; ONSET AGE; PATHOGENESIS; PCOL1A1 GENE; PROTEIN EXPRESSION; SCHOOL CHILD; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; IN VITRO STUDY; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COLLAGEN TYPE I; FEMALE; GENE EXPRESSION; HSP47 HEAT-SHOCK PROTEINS; HUMANS; IMIDAZOLES; IN VITRO TECHNIQUES; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIDINES; YOUNG ADULT;

EID: 84975317674     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2016.05.012     Document Type: Article

References (58)

1. Adachi T., Togashi H., Suzuki A., Kasai S., Ito J., Sugahara K., et al. NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology 2005, 41(6):1272-1281.
2. Armendariz-Borunda J., Islas-Carbajal M.C., Meza-Garcia E., Rincon A.R., Lucano S., Sandoval A.S., et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006, 55(11):1663-1665.
3. Bonner J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004, 15(4):255-273.
4. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 2000, 295(1):139-145.
5. Chavez-Blanco A., Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Cetina L., Candelaria M., et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol. Cancer 2005, 4(1):22.
6. Cuenda A., Rouse J., Doza Y.N., Meier R., Cohen P., Gallagher T.F., et al. Sb-203580 is a specific inhibitor of a map kinase homolog which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995, 364(2):229-233.
7. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 2004, 114(9):1308-1316.
8. Daniels C.E., Lasky J.A., Limper A.H., Mieras K., Gabor E., Schroeder D.R., et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 2010, 181(6):604-610.
9. de Graaf I.A., van der Voort D., Brits J.H., Koster H.J. Increased post-thaw viability and phase I and II biotransformation activity in cryopreserved rat liver slices after improvement of a fast-freezing method. Drug Metab. Dispos. 2000, 28(9):1100-1106.
10. de Graaf I.A., Olinga P., de Jager M.H., Merema M.T., de Kanter R., van de Kerkhof E.G., et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat. Protoc. 2010, 5(9):1540-1551.
11. Devissaguet J.P., Ammoury N., Devissaguet M., Perret L. Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundam. Clin. Pharmacol. 1990, 4(2):175-189.
12. Domitrovic R., Skoda M., Vasiljev Marchesi V., Cvijanovic O., Pernjak Pugel E., Stefan M.B. Rosmarinic acid ameliorates acute liver damage and fibrogenesis in carbon tetrachloride-intoxicated mice. Food Chem. Toxicol. 2013, 51:370-378.
13. Elferink M.G., Olinga P., van Leeuwen E.M., Bauerschmidt S., Polman J., Schoonen W.G., et al. Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol. Appl. Pharmacol. 2011, 253(1):57-69.
14. Gao Y., Dickerson J.B., Guo F., Zheng J., Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(20):7618-7623.
15. Hadi M., Westra I.M., Starokozhko V., Dragovic S., Merema M.T., Groothuis G.M. Human precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury. Chem. Res. Toxicol. 2013, 26(5):710-720.
16. Hinz B., Phan S.H., Thannickal V.J., Prunotto M., Desmouliere A., Varga J., et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 2012, 180(4):1340-1355.
17. Inoue T., Umezawa A., Takenaka T., Suzuki H., Okada H. The contribution of epithelial-mesenchymal transition to renal fibrosis differs among kidney disease models. Kidney Int. 2015, 87(1):233-238.
18. Iswandana R., Pham B.T., van Haaften W.T., Luangmonkong T., Oosterhuis D., Mutsaers H.A., et al. Organ- and species-specific biological activity of rosmarinic acid. Toxicol. in Vitro 2016, 32:261-268.
19. Jinnin M., Ihn H., Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol. Pharmacol. 2006, 69(2):597-607.
20. King T.E., Bradford W.Z., Castro-Bernardini S., Fagan E.A., Glaspole I., Glassberg M.K., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370(22):2083-2092.
21. Klassen L.W., Thiele G.M., Duryee M.J., Schaffert C.S., DeVeney A.L., Hunter C.D., et al. An in vitro method of alcoholic liver injury using precision-cut liver slices from rats. Biochem. Pharmacol. 2008, 76(3):426-436.
22. Kuo W.L., Yu M.C., Lee J.F., Tsai C.N., Chen T.C., Chen M.F. Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice. J. Gastrointest. Surg. 2012, 16(2):361-369.
23. Leveque D., Maloisel F. Clinical pharmacokinetics of imatinib mesylate. In vivo (Athens, Greece) 2005, 19(1):77-84.
24. Li G.S., Jiang W.L., Tian J.W., Qu G.W., Zhu H.B., Fu F.H. In vitro and in vivo antifibrotic effects of rosmarinic acid on experimental liver fibrosis. Phytomedicine 2010, 17(3-4):282-288.
25. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat. Rev. Nephrol. 2011, 7(12):684-696.
26. Liu Y., Meyer C., Xu C., Weng H., Hellerbrand C., ten Dijke P., et al. Animal models of chronic liver diseases. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304(5):G449-G468.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193(1):265-275.
28. Lyseng-Williamson K., Jarvis B. Imatinib. Drugs. 2001, 61(12):1765-1774. (discussion 75-6).
29. Mindikoglu A.L., Regev A., Bejarano P.A., Martinez E.J., Jeffers L.J., Schiff E.R. Imatinib mesylate (gleevec) hepatotoxicity. Dig. Dis. Sci. 2007, 52(2):598-601.
30. Minkin P., Zhao M., Chen Z., Ouwerkerk J., Gelderblom H., Baker S.D. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 874(1-2):84-88.
31. Olinga P., Merema M.T., Hof I.H., De Jager M.H., De Jong K.P., Slooff M.J., et al. Effect of cold and warm ischaemia on drug metabolism in isolated hepatocytes and slices from human and monkey liver. Xenobiotica 1998, 28(4):349-360.
32. Parsons C.J., Takashima M., Rippe R.A. Molecular mechanisms of hepatic fibrogenesis. J. Gastroenterol. Hepatol. 2007, 22(Suppl. 1):S79-S84.
33. Pellicoro A., Ramachandran P., Iredale J.P., Fallowfield J.A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 2014, 14(3):181-194.
34. Petersen M., Abdullah Y., Benner J., Eberle D., Gehlen K., Hucherig S., et al. Evolution of rosmarinic acid biosynthesis. Phytochemistry 2009, 70(15-16):1663-1679.
35. Rubino C.M., Bhavnani S.M., Ambrose P.G., Forrest A., Loutit J.S. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm. Pharmacol. Ther. 2009, 22(4):279-285.
36. Schaefer C.J., Ruhrmund D.W., Pan L., Seiwert S.D., Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev. 2011, 20(120):85-97.
37. Schaffert C.S., Duryee M.J., Bennett R.G., DeVeney A.L., Tuma D.J., Olinga P., et al. Exposure of precision-cut rat liver slices to ethanol accelerates fibrogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299(3):G661-G668.
38. Schuppan D., Kim Y.O. Evolving therapies for liver fibrosis. J. Clin. Invest. 2013, 123(5):1887-1901.
39. Sharma K., Ix J.H., Mathew A.V., Cho M., Pflueger A., Dunn S.R., et al. Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol. 2011, 22(6):1144-1151.
40. Starokozhko V., Abza G.B., Maessen H.C., Merema M.T., Kuper F., Groothuis G.M. Viability, function and morphological integrity of precision-cut liver slices during prolonged incubation: effects of culture medium. Toxicol. in Vitro 2015, 30(1 Pt B):288-299.
41. Stribos E.G., Luangmonkong T., Leliveld A.M., de Jong I.J., van Son W.J., JL H., et al. Precision-cut human kidney slices as a model to elucidate the process of renal fibrosis. Transl. Res. 2015.
42. Strumberg D., Clark J.W., Awada A., Moore M.J., Richly H., Hendlisz A., et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007, 12(4):426-437.
43. Tsukada S., Westwick J.K., Ikejima K., Sato N., Rippe R.A. SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J. Biol. Chem. 2005, 280(11):10055-10064.
44. van de Bovenkamp M., Groothuis G.M., Meijer D.K., Olinga P. Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro. J. Hepatol. 2006, 45(5):696-703.
45. van de Bovenkamp M., Groothuis G.M., Meijer D.K., Slooff M.J., Olinga P. Human liver slices as an in vitro model to study toxicity-induced hepatic stellate cell activation in a multicellular milieu. Chem. Biol. Interact. 2006, 162(1):62-69.
46. van de Bovenkamp M., Groothuis G.M., Meijer D.K., Olinga P. Liver slices as a model to study fibrogenesis and test the effects of anti-fibrotic drugs on fibrogenic cells in human liver. Toxicol. in Vitro 2008, 22(3):771-778.
47. Varela-Rey M., Montiel-Duarte C., Oses-Prieto J.A., Lopez-Zabalza M.J., Jaffrezou J.P., Rojkind M., et al. p38 MAPK mediates the regulation of alpha1(I) procollagen mRNA levels by TNF-alpha and TGF-beta in a cell line of rat hepatic stellate cells(1). FEBS Lett. 2002, 528(1-3):133-138.
48. Vickers A.E., Saulnier M., Cruz E., Merema M.T., Rose K., Bentley P., et al. Organ slice viability extended for pathway characterization: an in vitro model to investigate fibrosis. Toxicol. Sci. Off. J. Soc. Toxicol. 2004, 82(2):534-544.
49. Wang S., Wilkes M.C., Leof E.B., Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 2005, 19(1):1-11.
50. Watanabe T., Tajima H., Hironori H., Nakagawara H., Ohnishi I., Takamura H., et al. Sodium valproate blocks the transforming growth factor (TGF)-beta1 autocrine loop and attenuates the TGF-beta1-induced collagen synthesis in a human hepatic stellate cell line. Int. J. Mol. Med. 2011, 28(6):919-925.
51. Westra I.M., Pham B.T., Groothuis G.M., Olinga P. Evaluation of fibrosis in precision-cut tissue slices. Xenobiotica 2013, 43(1):98-112.
52. Westra I.M., Oosterhuis D., Groothuis G.M., Olinga P. Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. Toxicol. Appl. Pharmacol. 2014, 274(2):328-338.
53. Westra I.M., Oosterhuis D., Groothuis G.M., Olinga P. The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. PLoS ONE 2014, 9(4).
54. Xu S.W., Liu S., Eastwood M., Sonnylal S., Denton C.P., Abraham D.J., et al. Rac inhibition reverses the phenotype of fibrotic fibroblasts. PLoS ONE 2009, 4(10).
55. Yoshiji H., Noguchi R., Kuriyama S., Ikenaka Y., Yoshii J., Yanase K., et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288(5):G907-G913.
56. Zeisberg M., Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am. J. Phys. Cell Phys. 2013, 304(3):C216-C225.
57. Zhang J.J., Wang Y.L., Feng X.B., Song X.D., Liu W.B. Rosmarinic acid inhibits proliferation and induces apoptosis of hepatic stellate cells. Biol. Pharm. Bull. 2011, 34(3):343-348.
58. Zhao X.Y., Zeng X., Li X.M., Wang T.L., Wang B.E. Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin. Exp. Pharmacol. Physiol. 2009, 36(10):963-968.